Novel Radiofluorinated Nanobody PET Tracer for Preclinical Studies of TIM3 Expression
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00839 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Dongye Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China. Hauptthemen laut MEDLINE: Hepatitis A Virus Cellular Receptor 2, Positron-Emission Tomography, Fluorine Radioisotopes, Single-Domain Antibodies. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, The 2024 China Industrial Technology Infrastructure Public Service Platform Project.
Abstract (Originalsprache)
T-cell immunoglobulin and mucin domain-3 (TIM3) is an inhibitory checkpoint glycoprotein expressed on immune cells, particularly tumor-infiltrating lymphocytes (TILs), and plays a critical role in suppressing antitumor immune responses. While dual blockade of TIM3 and programmed cell death protein 1 (PD1) has shown promising results in enhancing immune responses in advanced cancers, the lack of reliable, noninvasive methods for detecting TIM3 expression in tumors remains a major challenge. To address this, we developed and characterized a novel positron emission tomography (PET) tracer, [18F]AlF-RESCA-HVCR2N2, based on a TIM3-specific nanobody labeled via [18F]AlF radiochemistry. The tracer demonstrated high specificity and affinity for TIM3 (KD = 4.644 nM) in vitro, enabling the clear visualization of TIM3-expressing lesions in tumor models through PET imaging. Dynamic imaging and kinetic analyses revealed favorable pharmacokinetics, and a preliminary correlation was observed between PET signal intensity and histologically assessed TIM3 expression in tumor tissues. These results highlight the potential of [18F]AlF-RESCA-HVCR2N2 as a sensitive and noninvasive tool for quantifying TIM3 expression in vivo, with significant implications for patient stratification, treatment monitoring, and the development of TIM3-targeted immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China.
- Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Shenzhen 518055, China.
- National Biomedical Imaging Center, Peking University, Beijing 100871, China.
- Department of Nuclear Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518…
- Institute of Medical Technology, Peking University Health Science Center, Peking University, Beijing 100191, China.
- Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluat…
ORCID-Profile: Yong Huang, Xiangxi Meng
Förderung
- National Natural Science Foundation of China
- The 2024 China Industrial Technology Infrastructure Public Service Platform Project
Zitieren
APA
Zheng, D., Huang, Y., Li, C., Lu, Y., Xie, Z., Liang, Y., Ren, Q., & Meng, X. (2025). Novel Radiofluorinated Nanobody PET Tracer for Preclinical Studies of TIM3 Expression. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00839
Vancouver
Zheng D, Huang Y, Li C, Lu Y, Xie Z, Liang Y, et al. Novel Radiofluorinated Nanobody PET Tracer for Preclinical Studies of TIM3 Expression. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00839
BibTeX
@article{Zheng2025,
author = {Zheng, Dongye and Huang, Yong and Li, Chengze and Lu, Yanye and Xie, Zhaoheng and Liang, Ying and Ren, Qiushi and Meng, Xiangxi},
title = {Novel Radiofluorinated Nanobody PET Tracer for Preclinical Studies of TIM3 Expression},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00839}
}
EUVIMED